CD8A and sarcoma: These findings are consistent with a recent study on sarcoma immune classes.11 In our ‘like-for-like’ comparison, the increase in CD8 estimates for tumors classified as hot versus cold was highly similar between all sarcoma subtypes and inflamed or immunotherapy-responsive cancers (Figure 3(f)).